Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

• Status: Enrolling by invitation
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TG Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol.

• Subjects must have completed at least 6 cycles of therapy on their current protocol.

Exclusion Criteria:

• Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.